사우디아라비아 혈당 검사지 시장 – 2031년까지의 산업 동향 및 예측

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF THE SAUDI ARABIA BLOOD GLUCOSE TEST STRIP MARKET

1.4 CURRENCY AND PRICING

1.5 LIMITATIONS

1.6 MARKETS COVERED

2 SAUDI ARABIA BLOOD GLUCOSE TEST STRIP MARKET : SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 DBMR TRIPOD DATA VALIDATION MODEL

2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.6 MULTIVARIATE MODELLING

2.7 PRODUCT TYPE SEGMENT LIFELINE CURVE

2.8 DBMR MARKET POSITION GRID

2.9 VENDOR SHARE ANALYSIS

2.1 MARKET END USER COVERAGE GRID

2.11 SECONDARY SOURCES

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PESTEL ANALYSIS

4.2 PORTER’S FIVE FORCES

4.3 MARKET PRACTICES

4.4 PRICING AND MARIGIN ANALYSIS

4.5 VOLUMETRIC ANALYSIS

4.6 MAIN TENDERS ANALYSIS

4.7 TECHNICAL PREFERENCES:

4.8 SAUDI ARABIA BLOOD GLUCOSE TEST STRIPS MARKET: PROCUREMENT PROCESS

4.8.1 THROUGH NUPCO

4.8.2 REQUIREMENTS FOR REGULATORY REGISTRATION AND TENDER APPLICATIONS:

4.9 SAUDI ARABIA BLOOD GLUCOSE TEST STRIPS MARKET, REIMBURSEMENT SCENARIO

4.9.1 TYPE 1 DIABETES

4.9.2 TYPE 2 DIABETES

4.9.3 PRE-DIABETES

5 SAUDI ARABIA BLOOD GLUCOSE TEST STRIPS MARKET, REGULATORY FRAMEWORK

5.1 OV,ERVIEW OF THE REGULATORY FRAMEWORK FOR BLOOD GLUCOSE STRIPS IN SAUDI ARABIA

5.2 REGULATORY FRAMEWORK FOR PUBLIC AND PRIVATE BLOOD GLUCOSE TEST STRIPS MARKET IN SAUDI ARABIA

5.2.1 REGULATIONS IN THE PUBLIC MARKET

5.2.2 REGULATIONS IN PUBLIC MARKET

5.3 REGULATORY FRAMEWORK FOR URBAN AND RURAL BLOOD GLUCOSE TEST STRIPS MARKET IN SAUDI ARABIA

5.4 REGISTRATION PROCESS AND REQUIREMENTS FOR RETAIL MARKET

5.4.1 PREPARATION AND DOCUMENTATION

5.4.2 SUBMISSION OF APPLICATION

5.4.3 REVIEW AND EVALUATION

5.4.4 SFDA APPROVAL

5.4.5 POST-MARKET SURVEILLANCE

5.4.6 RENEWAL AND MAINTENANCE

5.5 REGULATIONS FOR EXPIRED BLOOD GLUCOSE TEST STRIPS IN SAUDI ARABIA

5.5.1 HEALTHCARE WASTE MANAGEMENT

5.5.2 PRODUCT RECALL AND RETURN POLICIES

6 MARKET OVERVIEW

6.1 DRIVERS

6.1.1 RISING PREVALENCE OF DIABETES

6.1.2 GROWING ADOPTION OF SELF-MONITORING

6.1.3 RISING TECHNOLOGICAL ADVANCEMENTS IN BLOOD GLUCOSE TEST STRIP

6.1.4 RISING RESEARCH AND DEVELOPMENT ACTIVITIES IN BLOOD GLUCOSE TEST STRIP

6.2 RESTRAINTS

6.2.1 STRINGENT REGULATORY STANDARD FOR APPROVAL

6.2.2 ACCURACY AND RELIABILITY CONCERNS ASSOCIATED WITH BLOOD GLUCOSE TEST STRIPS

6.3 OPPORTUNITIES

6.3.1 GROWING EMPHASIS ON DISEASE MANAGEMENT AND PREVENTIVE CARE

6.3.2 GROWING DEMAND FOR POINT-OF-CARE TESTING

6.3.3 RISING HEALTHCARE EXPENDITURE

6.4 CHALLENGES

6.4.1 COST AND AFFORDABILITY OF BLOOD GLUCOSE TEST STRIPS

6.4.2 INADEQUATE REIMBURSEMENT FOR TEST STRIPS

7 SAUDI ARABIA BLOOD GLUCOSE TEST STRIPS MARKET, BY TYPE

7.1 OVERVIEW

7.2 THICK FILM ELECTROCHEMICAL FILMS

7.3 THIN FILM ELECTROCHEMICAL FILMS

7.4 OPTICAL STRIPS

8 SAUDI ARABIA BLOOD GLUCOSE TEST STRIPS MARKET, BY TECHNOLOGY

8.1 OVERVIEW

8.2 GLUCOSE OXIDASE

8.3 GLUCOSE DEHYDROGENASE

9 SAUDI ARABIA BLOOD GLUCOSE TEST STRIPS MARKET, BY MODALITY

9.1 OVERVIEW

9.2 USE AND THROW

9.2.1 TYPE 2 DIABETES

9.2.2 TYPE 1 DIABETES

9.2.3 PRE-DIABETES

9.2.4 GESTATIONAL DIABETES

9.3 BUILT-IN INDICATOR

9.3.1 TYPE 1 DIABETES

9.3.2 TYPE 2 DIABETES

9.3.3 PRE-DIABETES

9.3.4 GESTATIONAL DIABETES

10 SAUDI ARABIA BLOOD GLUCOSE TEST STRIP MARKET, BY PRICING

10.1 OVERVIEW

10.2 STANDARD

10.3 PREMIUM

11 SAUDI ARABIA BLOOD GLUCOSE TEST STRIP MARKET, BY SAMPLE

11.1 OVERVIEW

11.2 WHOLE BLOOD

11.3 PLASMA

12 SAUDI ARABIA BLOOD GLUCOSE TEST STRIP MARKET, BY MODE OF PURCHASE

12.1 OVERVIEW

12.2 OVER THE COUNTER

12.3 PRESCRIPTION BASED

13 SAUDI ARABIA HOSPITALS IN BLOOD GLUCOSE TEST STRIP MARKET, BY PACKAGING

13.1 OVERVIEW

13.2 50 STRIPS

13.3 100 STRIPS

13.4 25 STRIPS

14 SAUDI ARABIA HOSPITALS IN BLOOD GLUCOSE TEST STRIP MARKET, BY AGE GROUP

14.1 OVERVIEW

14.2 ADULT

14.3 GERAITRIC

14.4 PEDIATRIC

15 SAUDI ARABIA HOSPITALS IN BLOOD GLUCOSE TEST STRIP MARKET, BY APPLICATIONS

15.1 OVERVIEW

15.2 TYPE 2 DIABETES

15.3 TYPE 1 DIABETES

15.4 PRE-DIABETES

15.5 GESTATIONAL DIABETES

16 SAUDI ARABIA HOSPITALS IN BLOOD GLUCOSE TEST STRIP MARKET, BY END USER

16.1 OVERVIEW

16.2 HOME HEALTHCARE

16.3 HOSPITALS

16.3.1 PRIVATE

16.3.2 PUBLIC

16.4 DIAGNOSTIC LABORATORIES

16.5 OTHERS

17 SAUDI ARABIA HOSPITALS IN BLOOD GLUCOSE TEST STRIP MARKET, BY DISTRIBUTION CHANNEL

17.1 OVERVIEW

17.2 RETAIL SALES

17.2.1 HOSPITAL PHARMACY

17.2.2 DRUG STORES

17.2.3 ONLINE PHARMACY

17.3 OTHERS

18 SAUDI ARABIA BLOOD GLUCOSE TEST STRIPS MARKET, COMPANY LANDSCAPE

18.1 COMPANY SHARE ANALYSIS: SAUDI ARABIA

19 COMPANY PROFILE

19.1 F. HOFFMANN-LA ROCHE LTD

19.1.1 COMPANY SNAPSHOT

19.1.2 REVENUE ANALYSIS

19.1.3 PRODUCT PORTFOLIO

19.1.4 RECENT DEVELOPMENTS

19.2 LIFESCAN IP HOLDINGS, LLC

19.2.1 COMPANY SNAPSHOT

19.2.2 PRODUCT PORTFOLIO

19.2.3 RECENT DEVELOPMENTS

19.3 ABBOTT

19.3.1 COMPANY SNAPSHOT

19.3.2 REVENUE ANALYSIS

19.3.3 PRODUCT PORTFOLIO

19.3.4 RECENT DEVELOPMENT

19.4 ASCENSIA DIABETES CARE HOLDINGS AG.

19.4.1 COMPANY SNAPSHOT

19.4.2 PRODUCT PORTFOLIO

19.4.3 PRODUCT PORTFOLIO

19.5 SINOCARE INC.

19.5.1 COMPANY SNAPSHOT

19.5.2 PRODUCT PORTFOLIO

19.5.3 RECENT DEVELOPMENTS

19.6 ARKRAY, INC.

19.6.1 COMPANY SNAPSHOT

19.6.2 PRODUCT PORTFOLIO

19.6.3 RECENT DEVELOPMENT

19.7 BIONIME CORPORATION

19.7.1 COMPANY SNAPSHOT

19.7.2 PRODUCT PORTFOLIO

19.7.3 RECENT DEVELOPMENT

19.8 EASYMAX DIABETES CARE

19.8.1 COMPANY SNAPSHOT

19.8.2 PRODUCT PORTFOLIO

19.8.3 RECENT DEVELOPMENT

19.9 GENERAL LIFE BIOTECHNOLOGY CO., LTD.

19.9.1 COMPANY SNAPSHOT

19.9.2 PRODUCT PORTFOLIO

19.9.3 RECENT DEVELOPMENT

19.1 TRISTER

19.10.1 COMPANY SNAPSHOT

19.10.2 PRODUCT PORTFOLIO

19.10.3 RECENT DEVELOPMENT

20 QUESTIONNAIRE

21 RELATED REPORTS